Stephen Kanes
Equibles does not estimate personal net worth.
About Stephen Kanes
Centessa Pharmaceuticals plc reported in an 8-K filed June 24, 2026 that Stephen Kanes was terminated as Executive Officer, effective June 24, 2026. The proxy statement of Centessa Pharmaceuticals plc reports total compensation of $6,812,680 for Stephen Kanes in fiscal 2025, including a base salary of $519,034.
“Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.”
Affiliation history
-
Centessa Pharmaceuticals plc (CNTA)
Proxy statement
Start not stated–2026-06-24
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Centessa Pharmaceuticals plc (CNTA) | M.D., Ph.D. Chief Medical Officer | $519,034 | $6,812,680 |